Open AccessIncomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid
Author(s) -
John W. Eikelboom,
Graeme J. Hankey,
Jim Thom,
Deepak L. Bhatt,
Philippe Gabríel Steg,
Gilles Montalescot,
S. Claiborne Johnston,
Steven R. Steinhubl,
Koon-Hou Mak,
J. Donald Easton,
Christian W. Hamm,
Tingfei Hu,
Keith A.A. Fox,
Eric J. Topol
Publication year - 2008
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.108.768283
Subject(s) - medicine , aspirin , thromboxane , hazard ratio , urinary system , thromboxane b2 , placebo , myocardial infarction , clopidogrel , endocrinology , platelet , confidence interval , alternative medicine , pathology
Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydro thromboxane B(2) concentrations, has been associated with an increased risk of cardiovascular events. We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether there are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B(2) concentrations that could thereby reduce cardiovascular risk.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom